Literature DB >> 15731051

Antibody against V antigen prevents Yop-dependent growth of Yersinia pestis.

Alexander V Philipovskiy1, Clarissa Cowan, Christine R Wulff-Strobel, Sandra H Burnett, Edward J Kerschen, Donald A Cohen, Alan M Kaplan, Susan C Straley.   

Abstract

The V antigen (LcrV) of the plague bacterium Yersinia pestis is a potent protective antigen that is under development as a vaccine component for humans. LcrV is multifunctional. On the bacterial surface it mediates delivery of a set of toxins called Yops into host cells, and as a released protein it can cause production of the immunosuppressive cytokine interleukin-10 (IL-10) and can inhibit chemotaxis of polymorphonuclear neutrophils. It is not known how these mechanisms of LcrV operate, what their relative importance is, when they function during plague, and which are critical to protection by antibody. This study investigated several of these issues. C57BL/6 mice, mice unable to express IL-10, or mice with the macrophage lineage eliminated were treated with a protective anti-LcrV antibody or a nonprotective antibody against YopM and infected intravenously by Y. pestis KIM5 or a strain that lacked the genes encoding all six effector Yops. Viable bacterial numbers were determined at various times. The data indicated that Yops were necessary for Yersinia growth after the bacteria had seeded liver and spleen. Anti-LcrV antibody prevented this growth, even in IL-10-/- mice, demonstrating that one protective mechanism for anti-LcrV antibody is independent of IL-10. Anti-LcrV antibody had no effect on persistence in organs of Y. pestis lacking effector Yops, even though the yersiniae could strongly express LcrV, suggesting that Yops are necessary for building sufficient bacterial numbers to produce enough LcrV for its immunosuppressive effects. In vitro assays showed that anti-LcrV antibody could partially block delivery of Yops and downstream effects of Yops in infected macrophage-like J774A.1 cells. However, cells of the macrophage lineage were found to be dispensable for protection by anti-LcrV antibody in spleen, although they contributed to protection in liver. Taken together, the data support the hypothesis that one protective effect of the antibody is to block delivery of Yops to host cells and prevent early bacterial growth. The findings also identified the macrophage lineage as one host cell type that mediates protection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15731051      PMCID: PMC1064938          DOI: 10.1128/IAI.73.3.1532-1542.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  55 in total

Review 1.  Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen).

Authors:  Robert R Brubaker
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

2.  Response of guinea pig lungs to in vivo and in vitro cultures of Pasteurella pestis.

Authors:  G M FUKUI; W D LAWTON; W A JANSSEN; M J SURGALLA
Journal:  J Infect Dis       Date:  1957 Jan-Feb       Impact factor: 5.226

3.  Yersinia enterocolitica evasion of the host innate immune response by V antigen-induced IL-10 production of macrophages is abrogated in IL-10-deficient mice.

Authors:  Andreas Sing; Andreas Roggenkamp; Anna M Geiger; Jürgen Heesemann
Journal:  J Immunol       Date:  2002-02-01       Impact factor: 5.422

4.  Construction of defined F1 negative mutants of virulent Yersinia pestis.

Authors:  P L Worsham; M P Stein; S L Welkos
Journal:  Contrib Microbiol Immunol       Date:  1995

Review 5.  Interleukin-10 and the interleukin-10 receptor.

Authors:  K W Moore; R de Waal Malefyt; R L Coffman; A O'Garra
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

6.  Plague bacillus: survival within host phagocytes.

Authors:  W A Janssen; M J Surgalla
Journal:  Science       Date:  1969-02-28       Impact factor: 47.728

7.  Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages.

Authors:  Lynn Williams; Laura Bradley; Alexandra Smith; Brian Foxwell
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

8.  Genome sequence of Yersinia pestis KIM.

Authors:  Wen Deng; Valerie Burland; Guy Plunkett; Adam Boutin; George F Mayhew; Paul Liss; Nicole T Perna; Debra J Rose; Bob Mau; Shiguo Zhou; David C Schwartz; Jaqueline D Fetherston; Luther E Lindler; Robert R Brubaker; Gregory V Plano; Susan C Straley; Kathleen A McDonough; Matthew L Nilles; Jyl S Matson; Frederick R Blattner; Robert D Perry
Journal:  J Bacteriol       Date:  2002-08       Impact factor: 3.490

Review 9.  The virulence plasmid of Yersinia, an antihost genome.

Authors:  G R Cornelis; A Boland; A P Boyd; C Geuijen; M Iriarte; C Neyt; M P Sory; I Stainier
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

10.  In vivo comparison of avirulent Vwa- and Pgm- or Pstr phenotypes of yersiniae.

Authors:  T Une; R R Brubaker
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

View more
  39 in total

1.  Anti-LcrV antibody inhibits delivery of Yops by Yersinia pestis KIM5 by directly promoting phagocytosis.

Authors:  Clarissa Cowan; Alexander V Philipovskiy; Christine R Wulff-Strobel; Zhan Ye; Susan C Straley
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Characterization of Francisella tularensis outer membrane proteins.

Authors:  Jason F Huntley; Patrick G Conley; Kayla E Hagman; Michael V Norgard
Journal:  J Bacteriol       Date:  2006-11-17       Impact factor: 3.490

3.  Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV.

Authors:  Kristin L DeBord; Deborah M Anderson; Melanie M Marketon; Katie A Overheim; R William DePaolo; Nancy A Ciletti; Bana Jabri; Olaf Schneewind
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

Review 4.  Mammary gland macrophages: pleiotropic functions in mammary development.

Authors:  Kathryn L Schwertfeger; Jeffrey M Rosen; Donald A Cohen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-10       Impact factor: 2.673

5.  Humoral immune responses and protective efficacy of sequential B- and T-cell epitopes of V antigen of Yersinia pestis by intranasal immunization in microparticles.

Authors:  Jayaprakash Babu Uppada; Arif Azam Khan; Ajaz Ahmad Bhat; Ranjana Deshmukh; Donthamsetty Nageswara Rao
Journal:  Med Microbiol Immunol       Date:  2009-09-25       Impact factor: 3.402

6.  Amino acid and structural variability of Yersinia pestis LcrV protein.

Authors:  Andrey P Anisimov; Svetlana V Dentovskaya; Evgeniy A Panfertsev; Tat'yana E Svetoch; Pavel Kh Kopylov; Brent W Segelke; Adam Zemla; Maxim V Telepnev; Vladimir L Motin
Journal:  Infect Genet Evol       Date:  2009-10-14       Impact factor: 3.342

7.  Flagellin adjuvanted F1/V subunit plague vaccine induces T cell and functional antibody responses with unique gene signatures.

Authors:  Fahreta Hamzabegovic; Johannes B Goll; William F Hooper; Sharon Frey; Casey E Gelber; Getahun Abate
Journal:  NPJ Vaccines       Date:  2020-01-23       Impact factor: 7.344

Review 8.  Interleukin-10 and immunity against prokaryotic and eukaryotic intracellular pathogens.

Authors:  Joshua C Cyktor; Joanne Turner
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

9.  Substrains of 129 mice are resistant to Yersinia pestis KIM5: implications for interleukin-10-deficient mice.

Authors:  Joshua K Turner; John L Xu; Richard I Tapping
Journal:  Infect Immun       Date:  2008-10-27       Impact factor: 3.441

10.  Amino acid substitutions in LcrV at putative sites of interaction with Toll-like receptor 2 do not affect the virulence of Yersinia pestis.

Authors:  Wei Sun; Roy Curtiss
Journal:  Microb Pathog       Date:  2012-07-24       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.